Natural history of t(11;14) multiple myeloma (MM).

被引：2
|
作者：
Lakshman, Arjun
Moustafa, Muhamad Alhaj
Rajkumar, S. Vincent
Dispenzieri, Angela
Gertz, Morie A.
Buadi, Francis
Lacy, Martha
Dingli, David
Hayman, Suzanne R.
Gonsalves, Wilson I.
Kapoor, Prashant
Leung, Nelson
Lin, Yi
Go, Ronald S.
Kourelis, Taxiarchis
Lust, John Anthony
Russell, Stephen
Zeldenrust, Steven R.
Kyle, Robert A.
Kumar, Shaji
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8014
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Real world efficacy and safety of venetoclax in t(11;14) multiple myeloma in Hungary
    Szita, Virag
    Mikala, Gabor
    Kozma, Andras
    Fabian, Janos
    Hardi, Apor
    Alizadeh, Hussain
    Rajnics, Peter
    Varoczy, Laszlo
    Rejto, Laszlo
    Szendrei, Tamas
    Illes, Arpad
    Valyi-Nagy, Istvan
    Masszi, Tamas
    Varga, Gergely
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S86 - S87
  • [32] Liquid biopsy for t(11;14)/blc2 identification in multiple myeloma
    Spencer, Andrew
    Mithraprabhu, Sridurga
    Shah, Jaynish
    Choi, Kawa
    George, Ashley
    Hader, Carlos
    Khong, Tiffany
    CANCER RESEARCH, 2022, 82 (12)
  • [33] Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
    Leiba, Merav
    Duek, Adrian
    Amariglio, Ninette
    Avigdor, Abraham
    Benyamini, Noam
    Hardan, Izhar
    Zilbershats, Itay
    Ganzel, Chezi
    Shevetz, Olga
    Novikov, Ilya
    Cohen, Yossi
    Ishoev, Galina
    Rozic, Gabriela
    Nagler, Arnon
    Trakhtenbrot, Luba
    GENES CHROMOSOMES & CANCER, 2016, 55 (09): : 710 - 718
  • [34] The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic
    Jew, Scott
    Goldwater, Marissa-Skye
    Bujarski, Sean
    Regidor, Bernard
    Emamy-Sadr, Marsiye
    Swift, Regina
    Eades, Benjamin
    Said, Jonathan
    Berenson, James R.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 161 (01) : 16 - 23
  • [35] T(11;14) with multiple myeloma: Standard risk survival but slow and poor response
    Liu, Yuntong
    Xu, Jingyu
    Yan, Wenqiang
    Ma, Yueshen
    Li, Lingna
    Cui, Jian
    Lv, Rui
    Du, Chenxing
    Qiu, Lugui
    An, Gang
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5573 - 5581
  • [36] T(11;14) with Multiple Myeloma: Standard Risk Survival but Slow and Poor Response
    Liu, Yuntong
    Qiu, Lu-Gui
    An, Gang
    BLOOD, 2024, 144 : 4709 - 4709
  • [37] Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials
    Avigan, Zachary M.
    Richter, Joshua
    ONCOLOGY-NEW YORK, 2024, 38 (06):
  • [38] Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
    Kumar, Shaji
    Kaufman, Jonathan L.
    Gasparetto, Cristina
    Mikhael, Joseph
    Vij, Ravi
    Pegourie, Brigitte
    Benboubker, Lofti
    Facon, Thierry
    Amiot, Martine
    Moreau, Philippe
    Punnoose, Elizabeth A.
    Alzate, Stefanie
    Dunbar, Martin
    Xu, Tu
    Agarwal, Suresh K.
    Enschede, Sari Heitner
    Leverson, Joel D.
    Ross, Jeremy A.
    Maciag, Paulo C.
    Verdugo, Maria
    Touzeau, Cyrille
    BLOOD, 2017, 130 (22) : 2401 - 2409
  • [39] Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?
    Chakraborty, Rajshekhar
    Lentzsch, Suzanne
    CANCER, 2021, 127 (01) : 31 - 34
  • [40] Inferior Outcomes for Multiple Myeloma (MM) Patients (pts) Harbouring t(11;14) and the Promise of Venetoclax, Real-World Australian Retrospective
    Lim, Kenneth J. C.
    Talaulikar, Dipti
    Tan, Joanne L. C.
    Loh, Joanna
    Puvanakumar, Pratheepan
    Kuzich, James Anton
    Ho, Michelle
    Murphy, Matthew
    Zeglinas, Nicole
    Morgan, Sue
    Low, Michael S. Y.
    Routledge, David
    Lim, Andrew B. M.
    Gibbs, Simon D.
    Ninkovic, Slavisa
    BLOOD, 2021, 138
12345